Management rules on bioequivalence to be overhauled

The Korea Food and Drug Administration said on October 26 that matters concerning bioequivalence, including responsibility of sponsor and clinical center and operation of IRB, will be more rationalized.

Demonstrating the bioequivalence of different drugs requires proof of therapeutic equivalence, which justifies the substitution of one product for another.

Currently, bioequivalence can be...